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Abstract:
The complexity of modern medical practice is such that it is very unlikely 
that on any single issue we can give  a definitive answer in any 
circumstance, and in our view the  medical debate as to the use of 
particulate corticosteroid medicine  in axial  spinal blockade is  one such 
argument. The medical discussion  of the use of particulate 
corticosteroids has to be set against the uncertain  risk and benefits of 
axial spinal procedures in which the drugs are utilised, and in which the 
most likely catastrophic complication may occur with their use, and then, 
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Introduction
Medical treatments have never operated in the isolation of a simple doctor-patient 
relationship. Many other external factors need to be considered including relevant 
clinical evidence guidelines and medicolegal issues and specifically those of consent. 
The use of particulate steroids in axial spinal procedure is a case in point. While this 
treatment is commonly used, considerable doubts remain as to its effectiveness.   
Moreover the question arises as to whether the patient fully understand the risks 
and benefits of using the intended medicines and the procedure.
The use of particulate steroid in axial spinal blockade is a situation in which the 
specific particulate properties of the medicine may cause such catastrophic long-
term neurological problems through damage to the spinal cord via ischaemic 
mechanisms.  These catastrophic complications may follow even the most expertly 
performed procedure and frequently lead to a legal claim, based not on the standard 
of practice (which may have been immaculate as complications occur in even the 
most skilled hands) but instead on a failure to obtain adequate informed consent.  In 
such situations patients or clients are often heard to say something like ‘if I had known 
this might occur I would never have agreed to this treatment’. The ensuing investigation 
leaves a clinician involved in such a situation bewildered, and facing years of legal 
scrutiny and uncertainty.
This brief paper discusses the intersection of the major issues that have to be 
considered when prescribing particulate steroids in axial spinal procedures. 
The first question is whether there are specific risks associated with particulate 
steroids for axial spinal procedures which can be fully mitigated by the use of 
alternative and equally efficacious medicines? The second question relates to the 
fundamental issue of whether such axial spinal procedures in general should be 
performed in the first place. Thirdly, the question is whether the patient fully 
understands the complexity of the previous two issues and can give meaningful 
consent for the procedure and the particulate medicine; in particular, whether the 
patient has really given consent for the intervention if they understand that the 
benefits are likely to be at best modest and transient with the use of particulate 
steroids, and accompanied by an admittedly small risk of major catastrophic 
complications.
We will not try to reproduce all the evidence which is available concerning the 
possible complications of particulate steroids in axial spinal blockade in the 
literature. This has been more than adequately covered,1  but we will focus instead 
on addressing the intersection of the three questions given above 
The evidence base of particulate steroids causing catastrophic neurological damage 
in axial spinal procedures.
Scientific studies demonstrate that following arterial injection, particulate 
corticosteroid preparations may form aggregates which may act as emboli to block 
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small terminal arterioles in the brain and spinal cord. Methylprednisolone has the 
largest particle size, triamcinolone is intermediate, and betamethasone has the 
smallest. Dexamethasone is a solution and does not form particles or aggregates.2, 3
Arterial injection of particulate methylprednisolone has been shown to cause severe 
neurological consequences such as unconsciousness and cerebral haemorrhage.4, 5 
Particulate corticosteroid preparations have been associated, in published case 
reports, with neurological damage and vascular complications in humans.6, 7, 8
As a result of this evidence clinicians instead have turned to using non-particulate 
(liquid) corticosteroids for axial spinal procedures in an attempt to reduce the chance 
of such complications but concerns were raised that water soluble corticosteroids were 
perhaps less clinically efficacious than particulate corticosteroid formulations.9 
Overall the results following longer-term clinical outcomes after treatment comparing 
particulate and liquid corticosteroid preparations are equivocal. Park et al [2010] 
demonstrated that triamcinolone (a particulate preparation) reduced the visual 
analogue score (VAS) better than dexamethasone (a liquid).10 However, no difference 
was found between the groups using the McGill Pain Questionnaire or the Oswestry 
Disability Index. Kim & Brown [2011] found dexamethasone phosphate solution 
comparable to particulate methylprednisolone acetate in the treatment of lumbar 
radiculopathy, although dexamethasone demonstrated a trend toward less pain relief 
and a shorter duration of clinical efficacy.11 Feeley et al (2017) concluded that 
particulate steroids are not demonstrably better in relieving pain compared to their 
non-particulate counterparts and, in view of the safety concerns of particulate 
steroids, suggested it may be prudent to switch to non-particulates, or at the very least 
the dangers and alternatives should be flagged with the patient group as part of a shared 
decision-making process (our italics).12 
In a large retrospective observational study (3,645 lumbar transforaminal epidural 
steroid injections (TFESIs) performed on 2,634 subjects for radicular pain with or 
without radiculopathy) there was no evidence that dexamethasone was less effective 
in pain relief and functional improvement than particulate corticosteroids.13 A high 
quality trial on 78 consecutive subjects found that both triamcinolone and 
dexamethasone resulted in significant improvements in pain and function at 2 weeks, 
3 months, and 6 months, but without clear differences between groups, although 
patients in the dexamethasone group required slightly more injections than the 
triamcinolone group in order to achieve the same outcomes.14
Using the American Society of Anaesthesiologists Closed Claims database, epidural 
corticosteroid injections accounted for 83% of injections and 40% (114/284) of all 
chronic pain management claims.15 Significant nerve injury (with seven claims of 
quadriplegia/paraplegia) was also observed in 28 epidural corticosteroid claims but 
it was not specified how many related to use of particulate corticosteroid. Claims 
related to procedures performed at the level of the cervical spine comprised 22% of all 
claims related to chronic pain treatment, which suggested a relative increased risk in 
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this area of the spine.16  Of the 64 cases, there were nine (14%) cervical procedures 
associated with spinal cord infarction or stroke after intra-arterial injection. In five of 
these cases, spinal cord infarction followed cervical transforaminal injection of 
particulate corticosteroid. In three other claims, cervical transforaminal injection of 
particulate corticosteroid resulted in stroke, presumably by injection into the vertebral 
artery.
Concerns have also been raised whether corticosteroid formulations used for epidural 
administration should contain a preservative or not, although no preparations 
currently in the UK have a marketing authorization for epidural administration, so 
use by this route is currently an ‘off-label’ indication. There are, however, no 
documented adverse events from the placement of preservative-containing 
corticosteroids in the epidural space (although neurological injuries have been 
documented when the preservatives have been injected inadvertently by the 
intrathecal route). There have also been multiple cases of fungal infections caused by 
epidural and paraspinal injection of a contaminated glucocorticoid product in the US.  
Clinicians who elect to use preservative-free corticosteroids must carefully weigh the 
risks and benefits and address sterility concerns.17 
There also remains controversy as to any additional benefit from adding a 
corticosteroid to local anaesthetic for epidural administration. In a recent systematic 
review, high-quality evidence from multiple high‐quality randomized controlled 
trials identified that the combination of local anaesthetic with corticosteroid was 
effective in managing chronic spinal pain. Local anaesthetic with corticosteroid and 
local anaesthetic alone were equally effective in a range of spinal conditions except in 
disc herniation, where the combination was superior.18 
Based on the medical evidence the British Pain Society (BPS) and Faculty of Pain 
Medicine of the Royal College of Anaesthetists (FPMRCA) produced a Consensus 
Statement on the use of Corticosteroids for Neuraxial Procedures in the UK. They 
decided that due to the disproportionately large number of case reports of 
neurological complications related to the cervical region compared to the lumbar 
region, and also distinguishing between the interlaminar region compared to 
transforaminal injection, a case could be made for a clinician using different drugs in 
different regions. This position statement did, however, emphasise patient 
involvement in the decision-making progress.19
The conclusions of the BPS/FPM position statement are given below:
1. Particulate steroids must not be used for transforaminal cervical epidural 
injections on the basis of the risk of rare but catastrophic complications.
2. Whilst definitive recommendations cannot be given for the choice of soluble or
particulate steroid for injections in interlaminar cervical epidurals, clinicians 
should be aware that serious neurological complications can still occur.
3. Whilst definitive recommendations cannot be given for the choice of soluble or 
particulate steroid for injections in epidurals undertaken in other areas of the 
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spine (thoracic, lumbar and caudal), clinicians should be aware that serious 
neurological complications can occur with any route of administration, 
particularly if there is a history of previous spinal surgery.
4. Steroid preparations for epidural administration may carry a small risk of 
neurotoxicity with inadvertent intrathecal injection, due to the preservative 
preparation used. The clinician should carefully consider the formulation used.
5. The doctor must follow current GMC guidance on consent and record the 
discussion process. The discussion should ideally occur on an occasion prior to 
the procedure, as well as at the time of the procedure, to allow time for 
reflection.
6. The consent process should include discussion and documentation regarding 
indications, efficacy, safety and alternative treatments.
7. The use of corticosteroids in epidural injections is an indication that is outside 
the marketing authorisation (product licence). This information should also be 
incorporated into the consent process and documented in the medical records.
The issue arises with the above position statement, of course,  that if something is more 
likely to cause catastrophic neurological injury in the cervical region, why should 
particulate corticosteroids still be used at all in the lumbar region, even if the ever- 
present risk might be reduced in the lumbar region? It was accepted, however, that 
the risk of neurological injury was raised by the presence of altered anatomy (say in 
the case of prior spinal surgery).
What needs to be considered at this point in the discussion is point 6 in the FPM/BPS 
guidance, in order to focus on the role of the patient in the decision-making process.  
In particular, is the clinician entitled to make such a decision on behalf of the patient 
or should the patient have a greater role in the consenting process, in a scenario where 
there is likely a raised chance of a rare catastrophic neurological complication with 
particulate corticosteroid risk, compared to virtually no chance of such a complication 
with the use of non-particulate steroids?
Principles of consent 
The GMC has provided a framework for consent which all medical practitioners are 
expected to be familiar with and to follow (‘Consent: patients and doctors making 
decisions together’ GMC 2008).20 These principles have been strengthened in the draft 
updating new guidelines which are out for consultation.21 Briefly, the principles 
include the following:
a. listen to patients and respect their views about their health
b. discuss with patients what their diagnosis, prognosis, treatment and care 
involve
c. share with patients the information they want or need in order to make 
decisions
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d. maximise patients’ opportunities, and their ability, to make decisions for 
themselves
e. respect patients’ decisions.
There is recognition of the complexity and uncertainty in medical information and 
practice and the difficulty in applying appropriate information to a specific 
individual. In the past, the Bolam and Bolitho tests have provided the standard by 
which the Courts assess whether medical performance is or is not negligent. The Bolam 
test states that a doctor is not negligent and therefore has performed to an acceptable 
standard if he or she has acted in accordance with a practice accepted as proper by a 
responsible body of medical practitioners in that field of medicine. 22  Bolitho extended 
that principle to allow the Courts to reject a practice supported as proper by medical 
opinion if the court considered that it did not withstand logical analysis.23 However, 
in relation to consenting a patient and warning of the risks of treatment, the Supreme 
Court ruling in Montgomery (2015) has retrospectively superseded the older tests by 
imposing on a doctor the duty:24 
“to take reasonable care to ensure that a patient is aware of any
material risks involved in any recommended treatment, and of
any reasonable alternative or variant treatments.”
For these purposes a risk is material if a reasonable person in the patient’s position 
would be likely to attach significance to the risk, or if the doctor was, or should 
reasonably have been, aware that the particular patient would be likely to attach 
significance to it.  
Therefore, doctors must now ask themselves three questions (Sokol 2015):25
1) Does this patient know about the material risks of the treatment I am proposing?
2) Does this patient know about reasonable alternatives to this treatment?
3) Have I taken reasonable care to ensure that this patient actually knows this?
Within the consenting process relating to the use of steroids in central neuraxial 
procedures the following practices need to be demonstrated to have been performed:
1) There needs to be a provision of information in a manner which will allow for 
understanding by this particular patient. The complexity of information and 
issues that need to be considered means that in practice the prior provision and 
consideration of written information (for example a patient information leaflet, 
or similar, and a copy of the clinic letter) followed by a subsequent discussion 
is most likely to achieve this.  This consenting process will take time and will 
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usually require more than one occasion and should not be rushed. The fact that 
it has taken place, its duration and the key points discussed must be 
documented.
2) There needs to be a demonstration that those particular factors that are likely 
to matter to this particular patient have been discussed.  Risks or complications 
which may not concern another patient may be very important to this one.
3) There needs to be a demonstration that care was taken that this patient 
understands the implications of what is being done or suggested, what 
alternative or variant treatments exist, and the implications of not going ahead 
with the proposed treatment pathway.
It should also be noted that a patient who has been consented for treatment by Doctor 
A but on the day of the procedure is presented with Doctor B may have grounds for 
complaint should there be an adverse consequence to the procedure, if the choice of 
doctor was material to the giving of consent.  Therefore, where there is such a change 
of personnel, it is important that the patient is again consented and the further consent 
properly documented prior to the procedure.26
Medical consenting issues related to the use of epidural corticosteroids injections for 
pain:
In guiding the development of a patient information leaflet and guiding the 
discussion and the consenting with the patient, in our view the following need to be 
discussed.  (See also Appendix 1.)
 The use of corticosteroids in epidural injections is routine and probably does 
increase their efficacy compared to injections without corticosteroids.
 The use of particulate corticosteroids, particularly in the cervical region, is 
associated with more case reports of catastrophic complications.  In contrast, 
the use of non-particulate corticosteroid preparations such as dexamethasone 
has been reported in world literature to be associated with less than a handful 
of such catastrophic complications.
 Experience of the use of non-particulate steroid preparations is much more 
limited than particulate, and there are some concerns about the possible 
reduced efficacy of non-particulate corticosteroid preparations compared to 
particulate preparations.
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 Regardless of the position taken by a clinician in regards to the above factors, 
the current UK law on consent requires that a full and detailed discussion 
about the indications for, efficacy of, and types of drugs used in spinal 
injections needs to occur and be documented.
  Most people will receive these injections for acute or chronic spinal pain 
probably associated with radicular pain such as brachialgia (arm pain) or 
sciatica (leg pain), and it is likely that these types of pain tend over time to 
recur and, if already chronic, will most likely recur whatever therapy is 
offered. It is more likely than not that the injection will help in the short term 
(days to months) in relieving symptoms and may shorten an attack of pain, so 
in effect ‘curing that episode of pain’, but most studies suggest that such 
injections are unlikely to change the long-term clinical course of pain and 
disability, or there is no high quality evidence to support such a change.27, 28, 
29 
In conclusion, the current evidence suggests steroids in general may be a useful 
addition to epidural blockade but particulate steroids are likely to be associated with 
an increased risk of catastrophic complications compared to non-particulate 
corticosteroid preparations, especially with neuroforaminal injections in the cervical 
region and more generally in the neuraxsis  after spinal surgery. Non-particulate 
corticosteroids are probably going to work as well as particulate formulations, but 
there is no high-quality evidence that any corticosteroid-based axial spinal 
procedures in themselves are likely to change the long-term clinical outcome in an 
individual patient. Once the issue of fully informed patient involvement in the 
consenting process is also considered, the future role of any corticosteroid-based 
treatments in the treatment of axial spinal derived pain is likely to be diminished.
In our view some of the main issues that need to be addressed with the patient 
during the consenting process for pain-related procedures are given in appendix 1, 
an issue also discussed elsewhere.30, 31, 32  However, the exact issues discussed will be 
those relevant to the particular case and individual patient and therefore this list will 
need to be adapted on a case by case basis and cannot be a list of every issue which 
might need to be considered. We recommend that a patient information leaflet or 
similar be considered to address these issues prior to a final discussion about 
whether to proceed with a spinal injection.
Page 7 of 11
https://mc.manuscriptcentral.com/bjpain































































List of possible questions that should be addressed during the consenting process for an 
axial spinal procedure 
1) What is the natural history of this spinal condition? In particular, what are the 
chances that my condition will improve or deteriorate without this spinal 
injection and what are likely to be the implications of that for me? 
2) What are the risks of a) minor complications (short-term non-life changing 
effects) b) major complications (life changing effects, including rare 
catastrophic neurological complications) as a result of the injection?
3) What difference does the addition of corticosteroid make to the efficacy of this 
injection?
4) Does the use of a non-particulate over particulate corticosteroid make the 
injection safer, and if so, by how much?  
5) Does the use of a non-particulate over particulate corticosteroid make the 
spinal injections less effective?
6) How do the risks and potential benefits of the injection compare if I have no 
corticosteroid in it at all?
7) Are cervical injections more dangerous than injections in the thoracic and 
lumbar region? If so why, and what difference does the use of non-particulate 
corticosteroids make to that risk?
8) Are there alternatives to this invasive injection such as other oral analgesics or 
oral corticosteroids, how effective are they likely to be, and what possible 
complications might there be in such treatment?
9) Will this injection work for me a) in the short term (i.e. days to weeks and 
perhaps months) and b) in the long term (i.e. many months to years or 
permanently)? Alternatively, following a spinal injection will my spinal 
condition recur, and if so, over what period of time?
10) If this injection works for me, will I need it again?
11) If this injection does work initially but the benefit is lost over time, is this 
injection simply delaying a definitive treatment (such as surgery) which I 
would require in any case? 
12) What are the risks of surgery compared to these injections, and how likely is 
surgery to be an effective (long-term) mode of treatment?
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13) Are there safer ways of performing the injections, and does the use of contrast 
and imaging make a difference to the risk?
14) Does the presence of other agents such as preservative in the corticosteroid 
preparation have any possible adverse effect on me?
15) Does the use of preservative-free injections mean that I am more likely to get 
an infection from a possible contaminated batch of drug?
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